Leeds, United Kingdom

Jason Gill

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 5.9

ph-index = 3

Forward Citations = 15(Granted Patents)


Location History:

  • Rothwell Haigh, GB (2015)
  • Bradford, GB (2014 - 2019)
  • Leeds, GB (2018 - 2021)

Company Filing History:


Years Active: 2014-2021

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Jason Gill: Innovator in Cancer Treatment

Introduction

Jason Gill is a prominent inventor based in Leeds, GB, known for his significant contributions to cancer treatment through innovative compounds. With a total of 8 patents to his name, Gill has focused on developing methods that utilize vascular disrupting agents to target cancer effectively.

Latest Patents

Among his latest patents, Gill has developed methods of treating cancer using compounds containing a vascular disrupting agent. This invention relates to prodrugs of vascular disrupting agents that comprise a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site. These prodrugs are designed for targeted cancer treatment. Additionally, he has patented compounds that include a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site, which are also useful in cancer treatment.

Career Highlights

Throughout his career, Jason Gill has worked with notable companies such as Incanthera Limited and Ellipses Pharma Limited. His work in these organizations has contributed to advancements in cancer therapies and has positioned him as a key figure in the field of medical innovation.

Collaborations

Some of his notable coworkers include Paul Loadman and Laurence Patterson, who have collaborated with him on various projects aimed at enhancing cancer treatment methodologies.

Conclusion

Jason Gill's innovative work in developing targeted cancer treatments through vascular disrupting agents showcases his commitment to advancing medical science. His contributions are paving the way for more effective cancer therapies, making a significant impact in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…